Calfat Alexandre Campeau, Gosselin Maude, Sirois Caroline
VITAM-Sustainable Health Research Center, Quebec, Canada.
Faculty of Pharmacy, Université Laval, Quebec, Canada.
Basic Clin Pharmacol Toxicol. 2025 Jun;136(6):e70050. doi: 10.1111/bcpt.70050.
Deprescribing is a patient-centred process in which a healthcare professional reduces or stops medications to improve health outcomes. Since late 2022, community pharmacists in Québec, Canada, have been able to bill for deprescribing interventions, enabling more robust deprescribing research in large cohort studies.
This study aimed to assess the prevalence of deprescribing claims in Québec community pharmacies from January 1, 2023, to November 30, 2024, and to identify the most commonly deprescribed medication classes.
We analysed the total number of deprescribing claims submitted by pharmacists during this period and categorized deprescribed medications using the American Hospital Formulary Service classification.
Over 90 000 claims were submitted for deprescribing interventions, with most involving central nervous system medications. Although the number of claims increased over time, the overall volume remained modest.
While limitations remain, such as the gradual adoption of billing interventions, Québec's reimbursement model for deprescribing interventions provides an important framework for research, offering a mechanism to study deprescribing in real-world settings.
减药是一个以患者为中心的过程,医疗保健专业人员通过减少或停用药物来改善健康结果。自2022年末以来,加拿大魁北克省的社区药剂师能够为减药干预措施计费,这使得在大型队列研究中开展更有力的减药研究成为可能。
本研究旨在评估2023年1月1日至2024年11月30日期间魁北克社区药房减药计费申请的发生率,并确定最常被减用的药物类别。
我们分析了在此期间药剂师提交的减药计费申请总数,并使用《美国医院处方集服务》分类法对减用药物进行分类。
提交了超过90000份减药干预申请,其中大多数涉及中枢神经系统药物。尽管申请数量随时间增加,但总体数量仍然不多。
虽然仍存在局限性,如计费干预措施的逐步采用,但魁北克省减药干预措施的报销模式为研究提供了一个重要框架,提供了一种在现实环境中研究减药的机制。